Jody A. Charnow

Editor https://www.renalandurologynews.com

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

An Update on Robotic-Assisted Partial Nephrectomy

Kidney Cancer

RCC With Isolated Lymph Node Metastases Has Poor Prognosis After Surgery

Jody A. Charnow

October 9, 2019

Following nephrectomy for renal cell carcinoma with lymph node involvement, patients have a 5-year survival rate of only 28%, a new study found.

Bladder Cancer

Bladder Cancer Linked to Stewed, Roasted Meat

Jody A. Charnow

October 4, 2019

High intake of stewed or roasted meat, but not boiled, fried, or preserved meat, is associated with increased odds of bladder cancer, a case-control study found.

Transplantation

Donor Kidney Use Still Suboptimal

Jody A. Charnow

October 3, 2019

Study reveals nearly 18% discard rate in the United States.

Study Suggests Tough Smoking Laws Might Lower Suicide Risk

Prostate Cancer

Longer Smoking Duration Predicts Higher Prostate Cancer Recurrence Risk

Jody A. Charnow

October 3, 2019

In a prospective cohort study of men who underwent radical treatment for prostate cancer, smoking duration of 10 or more years among ever-smokers was associated an increased risk of biochemical recurrence.

Close to 60% of all patients with VHL will develop RCC or renal cysts.

Kidney Cancer

Durable Positive Effects of First-Line Pembrolizumab in Advanced RCC Reported

Jody A. Charnow

October 2, 2019

Updated follow-up of patients in the KEYNOTE-427 trial showed that first-line pembrolizumab for advanced clear cell renal cell carcinoma exerts favorable antitumor activity after a median 23 months of follow-up.

Better mCRPC Survival with Docetaxel Followed by Abiraterone

Prostate Cancer

Upfront Antiandrogens, Chemotherapy for mCRPC Offer Similar Survival

Jody A. Charnow

October 2, 2019

Men who receive first-line abiraterone or enzalutamide or first-line docetaxel treatment for metastatic castration-resistant prostate cancer have similar overall survival, a prospective, observational cohort study found.

Low Testosterone Before ADT Predicts Poor Prognosis in Metastatic PCa

Prostate Cancer

Chemotherapy for mCRPC Improves Survival, Real-World Study Shows

Jody A. Charnow

October 1, 2019

Men with castration-resistant prostate cancer treated with abiraterone or enzalutamide and received no chemotherapy have a significantly higher risk of death than those who receive chemotherapy, according to an analysis of real-world data.

Prostate Cancer

PARP-Inhibiting Drug May Improve mCRPC Outcomes

Jody A. Charnow

September 30, 2019

In a phase 3 trial of men with metastatic castration-resistant prostate cancer and altered DNA repair genes, olaparib-treated patients had significantly longer radiographic progression-free survival compared with enzalutamide or abiraterone recipients.

At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progre

Bladder Cancer

Immunotherapy + Chemo May Improve Outcomes in Metastatic Urothelial Cancer

Jody A. Charnow

September 30, 2019

First-line treatment with both atezolizumab and platinum-based chemotherapy (PBC) is associated with prolonged progression-free survival vs PBC alone in patients with metastatic urothelial cancer, a study found.

Bladder Cancer

NAC Increases Pathologic Complete Response Rate in High-Risk MIBC

Jody A. Charnow

September 30, 2019

In a study of patients with high-risk muscle-invasive bladder cancer, patients who received cisplatin-based neoadjuvant chemotherapy had a 3.6 times higher rate of pathologic complete response compared with those who had upfront radical cystectomy.

Next post in Bladder Cancer